1
|
Green PH and Cellier C: Celiac disease. N
Engl J Med. 357:1731–1743. 2007. View Article : Google Scholar : PubMed/NCBI
|
2
|
Scaramuzza AE, Mantegazza C, Bosetti A and
Zuccotti GV: Type 1 diabetes and celiac disease: The effects of
gluten free diet on metabolic control. World J Diabetes. 4:130–134.
2013. View Article : Google Scholar : PubMed/NCBI
|
3
|
Hooft C, Roels H and Devos E: Diabetes and
coeliac disease. Lancet. 2:11921969.PubMed/NCBI
|
4
|
Secchiero P and Zauli G: TNF-related
apoptosis-inducing ligand and the regulation of hematopoiesis. Curr
Op Hematol. 15:42–48. 2008. View Article : Google Scholar : PubMed/NCBI
|
5
|
Secchiero P, Gonelli A, Celeghini C, et
al: Activation of the nitric oxide synthase pathway represents a
key component of tumor necrosis factor-related apoptosis-inducing
ligand-mediated cytotoxicity on hematologic malignancies. Blood.
98:2220–2228. 2001. View Article : Google Scholar
|
6
|
Vinay DS and Kwon BS: The tumour necrosis
factor/TNF receptor superfamily: therapeutic targets in autoimmune
diseases. Clin Exp Immunol. 164:145–157. 2011. View Article : Google Scholar : PubMed/NCBI
|
7
|
Di Bartolo BA, Chan J, Bennett MR,
Cartland S, Bao S, Tuch BE and Kavurma MM: TNF-related
apoptosis-inducing ligand (TRAIL) protects against diabetes and
atherosclerosis in ApoE−/− mice. Diabetologia.
54:3157–3167. 2011.PubMed/NCBI
|
8
|
Zauli G, Toffoli B, di Iasio MG, Celeghini
C, Fabris B and Secchiero P: Treatment with recombinant tumor
necrosis factor-related apoptosis-inducing ligand alleviates the
severity of streptozotocin-induced diabetes. Diabetes.
59:1261–1265. 2010. View Article : Google Scholar
|
9
|
Tornese G, Iafusco D, Monasta L, et al:
The levels of circulating TRAIL at the onset of type 1 diabetes are
markedly decreased in patients with ketoacidosis and with the
highest insulin requirement. Acta Diabetol. 51:239–246. 2014.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Zauli G, Melloni E, Capitani S and
Secchiero P: Role of full-length osteoprotegerin in tumor cell
biology. Cell Molecular Life Sci. 66:841–851. 2009. View Article : Google Scholar : PubMed/NCBI
|
11
|
Volpato S, Ferrucci L, Secchiero P, et al:
Association of tumor necrosis factor-related apoptosis-inducing
ligand with total and cardiovascular mortality in older adults.
Atherosclerosis. 215:452–458. 2011. View Article : Google Scholar
|
12
|
Secchiero P, Corallini F, Ceconi C,
Parrinello G, Volpato S, Ferrari R and Zauli G: Potential
prognostic significance of decreased serum levels of TRAIL after
acute myocardial infarction. PloS One. 4:e44422009. View Article : Google Scholar : PubMed/NCBI
|
13
|
Secchiero P, Corallini F, Beltrami AP, et
al: An imbalanced OPG/TRAIL ratio is associated to severe acute
myocardial infarction. Atherosclerosis. 210:274–277. 2010.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Xiang G, Zhang J, Ling Y and Zhao L:
Circulating level of TRAIL concentration is positively associated
with endothelial function and increased by diabetic therapy in the
newly diagnosed type 2 diabetic patients. Clin Endocrinol (Oxf).
80:228–234. 2013. View Article : Google Scholar
|
15
|
Lahdenperä AI, Hölttä V, Ruohtula T, et
al: Up-regulation of small intestinal interleukin-17 immunity in
untreated coeliac disease but not in potential coeliac disease or
in type 1 diabetes. Clin Exp Immunol. 167:226–234. 2012.PubMed/NCBI
|
16
|
Pagliari D, Cianci R, Frosali S, Landolfi
R, Cammarota G, Newton EE and Pandolfi F: The role of IL-15 in
gastrointestinal diseases: A bridge between innate and adaptive
immune response. Cytokine Growth Factor Rev. 24:455–466. 2013.
View Article : Google Scholar : PubMed/NCBI
|